±³¾°½éÉÜ£º¸¹Ö÷¶¯ÂöÁö(abdominalaorticaneurysm,AAA)ÊÇÒ»ÖÖ³£¼ûµÄ¶¯ÂöÍËÐÐÐÔ¼²²¡£¬³£±íÏÖΪÉöϸ¹Ö÷¶¯ÂöÁöÑùÀ©ÕÅ£¬Æä¶¨ÒåΪ¸¹Ö÷¶¯ÂöÖ±¾¶À©ÕÅΪÕý³£Ö±¾¶µÄ1.5±¶ÒÔÉÏ»òÉö¶¯Âö·Ö²æÒÔϵÄÖ÷¶¯ÂöÖ±¾¶¡Ý30mm¡£AAAµÄΣÏÕÒòËØ°üÀ¨ÄêÁä¡¢ÄÐÐÔ¡¢¼Ò×åÊ·¡¢ÎüÑÌ¡¢ÂýÐÔ×èÈûÐԷμ²²¡¡¢¸ßѪ֬ºÍ¸ßѪѹµÈ¡£AAAÔÚÄÐÐÔÖеķ¢²¡ÂʸßÓÚÅ®ÐÔ£¬ÓÐÑо¿±íÃ÷ÄÐÅ®±ÈÀýΪ4:1£¬µ«Í¨³£ÔÚÆÆÁÑǰÎÞÖ¢×´£¬AAAÆÆÁѵ¼Ö»¼ÕßµÄ×ÜÌåËÀÍöÂʳ¬¹ý80%¡£AAAµÄÖ÷Òª²¡Àí¸Ä±äΪÂýÐÔÑ×Ö¢¡¢Ï¸°ûÍâ»ùÖʽµ½â¡¢Ñª¹Üƽ»¬¼¡Ï¸°ûµòÍöµÈ¡£ÓÉÓÚAAA·¢²¡»úÖÆ¸´ÔÓ£¬Ä¿Ç°Éв»ÍêÈ«Çå³þ£¬µ±Ç°ÆÕ±éÈÏΪAAAÓë¼Ò×åÒÅ´«¡¢Ñ×Ö¢·´Ó¦¡¢Ï¸°ûÍâ»ùÖÊÖØËܵÈÖî¶àÒòËØÓйأ¬ÆäÉæ¼°ÃâÒßѧ¡¢·Ö×ÓÉúÎïѧ¼°»ùÒò×éѧµÈÁìÓò¡£Òò´Ë£¬¶¯ÎïÄ£Ð͵Ľ¨Á¢¶ÔÑо¿AAAµÄ·¢²¡»úÖÆ¡¢Ì½ÌÖÔçÆÚµÄÕï¶ÏºÍѰÕÒÓÐЧµÄÖÎÁÆ´ëÊ©¾ßÓÐÖØÒªÒâÒå¡£
Ó¦Ó÷½Ïò£ºÑ»·ÏµÍ³Ïà¹Ø¿ÎÌâ¡£
¹Ø¼ü´Ê£º¸¹Ö÷¶¯ÂöÁöÄ£ÐÍ¡¢AAA¡¢Abdominalaorticaneurysm
ʵÑ鶯Î´óÊóƷϵ£ºSD¡¢Wistar£»ÖÜÁ䣺6-8ÖÜ£»ÐÔ±ð²»ÏÞ¡£
ÔìÄ£·½·¨£º²ÉÓø¹Ö÷¶¯Âö¹à×¢µ¯Á¦µ°°×ø¹¹½¨¸¹Ö÷¶¯ÂöÁöÄ£ÐÍ¡£
ͼ1Ä£ÐÍʾÒâͼ

Ä£ÐÍÑéÖ¤£ºÊõºó½âÆÊ¶¯Îï²âÁ¿µ¯Á¦µ°°×ø¹à×¢¶ÎµÄѪ¹ÜµÄÖ±¾¶£¬Ö±¾¶´óÓÚÊõǰ
Ö±¾¶150%ÒÔÉϱíʾÔìÄ£³É¹¦¡£

²Î¿¼ÎÄÏ×£ºMelinLeanderGaarde,etal.CycloastragenolInhibitsExperimental
AbdominalAorticAneurysmProgression.[J]Biomedicines,2022,10:undefined.
£¨IF=4.717£©
ÆäËû¼ì²â£ºÈç»îÌ峬Éù¼ì²âµÈ¡£
ʵÑéÍâ°ü ÏëÁ˽â¸ü¶àÇë¹Ø×¢£º



